



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Joseph G. Furst

For

IRRADIATED STENT COATING

Serial No.

10/810,356

Filed

March 26, 2004

Group Art Unit

3731

Our Docket

ICON 2 13110-1

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

In accordance with the requirements of 37 CFR 1.97 and 37 CFR 1.98, Applicant cites the references which are identified on the enclosed form PTO-1449.

Consideration of the references and placement on the record is respectfully requested.

Respectfully submitted

FAY, SHARPE, FAGAN, MANNICH & MCKEE

I hereby certify that this correspondence is being deposite with the United States Postal Service as first class mail an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

By:

ROBERT V. VICKERS

Reg. No. 19,504

1100 Superior Avenue, 7th Floor Cleveland, Ohio 44114-2579

Telephone: (216) 861-5582 Facsimile: (216) 241-1666 Please type a plus sign (+) inside this Box→

1449A/PTO Rev. 10/95

0	PE	3
2	1 9 2005	35 3 <i>3</i> 3
U.S. U	Department of	Sommerc

LIST OF PRIOR ART CITED BY
APPLICANT

(use as many sheets as necessary)

	Complete if Known	
Application Number	10/810,356	
Filing Date	March 26, 2004	
First Named Inventor	Furst, Joseph G.	
Group Art Unit	3731	
Examiner Name	Unknown	
Attorney Docket Number	ICON 2 13110-1	

				U. S. PATENT DOCUM	ENTS	
Examiner Initials*	Cite No.1	U.S. Patent		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
iiiiiiais	140.	Number	Kind Code (if known)	or once position	MM-DD-YYYY	Figures Appear
		4,733,665				
		4,776,337				
		5,037,392			<u> </u>	
		5,116,318				
	<u>.</u>	5,283,257		ļ.,,		
		5,370,681				
		5,417,981				
		5,609,629				
		5,733,925				
		5,811,447				
		5,824,049				
		5,873,904	•			
		5,981,568				
		6,074,659				
		6,096,070				
		6,120,847				
		6,156,373				
		6,171,609				
		6,206,916				
		6.245.537				

			FOR	EIGN P	ATENT DOCUMENTS			
Cite		oreign Patent Docum				Date of Publication	Pages, Columns, Lines, Where Relevant	
No.	Office ³	Number Kind Code ⁵ (if known)		Applicant of Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear	T⁵	
	у-							
	<u> </u>							<u> </u>
	ļ							
-								
								+
-	 							-
	 							
		 			· · · · · · · · · · · · · · · · · · ·	0.3.0		
-	 					 		+
	Cite No.	No.1 Office3	No. Office ³ Number ⁴	Cite No.' Office' Number' Kind (if k	Cite No.1 Office Source Number Number (if known)	No. Office Number Kind Code Applicant of Cited Document (if known)	Cite No.' Office's Number's Kind Code's (if known) Name of Patentee or Applicant of Cited Document MM-DD-YYYY	Cite No.' Office' Number' Kind Code' Applicant of Cited Document MM-DD-YYYY Name of Patentee or Applicant of Cited Document MM-DD-YYYY Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1⁶ if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

1449A/PTO Rev. 10/95			U.S. Department of Commerce Patent and Trademark Office		Complete if Known	
				Application Number	10/810,356	
LIS	T OF PRIOR	ART	CITED BY	Filing Date	March 26, 2004	
	APPLI	CAN	T	First Named Inventor	Furst, Joseph G.	
	(use as many shee	oto oo oo	neces./\	Group Art Unit	3731	
	(use as many snee	ets as nece	ssary)	Examiner Name	Unknown	
Sheet	2	of	6	Attorney Docket Number	ICON 2 13110-1	

U. S. PATENT DOCUMENTS									
Examiner Cite No.	U.S. Patent		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
minais	140.	Number	Kind Code (if known)	or offen bochment	MM-DD-YYYY	Figures Appear			
		6,258,121		,					
		6,268,390							
		6,287,628							
		6,273,913							
		6,299,604							
		6,306,421							
		6,322,847							
		6,358,989							
		6,356,600							
		6,368,658							
		6,369,065							
		6,379,379							
		6,379,381		0					
		6,436,133							
		6,491,938							
		6,515,009							
		6,530.951		,					
		6,545,097							
		6,555,157							
		6.569.195							

				FOREIGN	PATENT DOCUMENTS			
Examiner Initials*	Cite No.	ı	Foreign Patent Docum	ent	Name of Patentee or Applicant of Cited Document	Date of Publication	Pages, Columns, Lines, Where Relevant	
Initials*	No.'	Office ³	Number ^a	Kind Code ^s (if known)	Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
								1

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1⁶ if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

ease	type	я	nlus	sion	(+)	inside	this	Box→	æ

1449A/PTO Rev. 10/95	U.S. Department of Commerce Patent and Trademark Office	Complete if Known		
		Application Number	10/810,356	
LIST OF PRIOR A	RT CITED BY	Filing Date	March 26, 2004	
APPLIC	ANT	First Named Inventor	Furst, Joseph G.	
(use as many sheets a	es nacessan/)	Group Art Unit	3731	
(use as many sneets a	is necessary)	Examiner Name	Unknown	
Sheet 3	of 6	Attorney Docket Number	ICON 2 13110-1	

				U. S. PATENT DOCUM	ENIS	Dance Columns
Examiner Cite No.	Cite	U.S. Patent I	Documents	Name of Patentee or Applicant of Cited Document	Date of Publication	Pages, Columns, Lines, Where Relevant
Initials*	No.'	Number	Kind Code (if known)	of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		6,569,441				
		6,585,764				
		6,599,275				
		6,599,928				·
		6,607,598				
		6,623,521				
		6,624,138				,
		6,652,575				
		6,656,506				
		6,656,966				
		6,663,881				
		6,720,350				
		6,730,064				
		6,730,349				
		6,734,194				
		6,743,805				
		6,753,071				
		6,759,431				
		6,770,729				
		6,774,278				

			•	FOR	EIGN F	PATENT DOCUMENTS	· · · · · · · · · · · · · · · · · · ·		
Examiner Initials*	Cite No.1		Foreign Patent Docume			Name of Patentee or Applicant of Cited Document	Date of Publication	Pages, Columns, Lines, Where Relevant	
Initials*	No.'	Office	Number	Kind (if k	Code° nown)	Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
								,	
							•		
~									
									\mathbf{I}

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1⁶ if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

				٠.،	inside	46:-	0	\mathbf{m}
ease	туре а	pius	sign	(+)	ınsıde	เกเร	BOX→	т

1449A/PTO Rev. 10/95	······································		U.S. Department of Commerce Patent and Trademark Office		Complete if Known	
				Application Number	10/810,356	
LIS	T OF PRIOR	ART	CITED BY	Filing Date	March 26, 2004	
	APPLI	CAN	Τ [First Named Inventor	Furst, Joseph G.	
	(use as many shee	ets as nece	lyness	Group Art Unit	3731	
	· · · · · · · · · · · · · · · · · · ·			Examiner Name	Unknown	
Sheet	4	of	6	Attorney Docket Number	ICON 2 13110-1	

				U. S. PATENT DOCUME	NTS	
Examiner Initials*	Cite No.	U.S. Patent Docume Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)	<u> </u>	MM-DD-YYYY	Figures Appear
		6,780,849			1	
		6,783,793				
	<u> </u>	6,808,536			<u> </u>	
		Pub. No. 2002-0032414				
		Pub. No. 2003-0028243				
		Pub. No. 2003-0028244				
		Pub. No. 2003-0036794				
		Pub. No. 2004-0047909				
		Pub. No. 2004-0219223				
		Pub. No. 2004-0243225				
				Ϋ́		
						_
				1		

			· · · · · · · · · · · · · · · · · · ·	FOF	REIGN P	ATENT DOCUMENTS			
Examiner Initials*	Cite No.1		Foreign Patent Docum			Name of Patentee or	Date of Publication	Pages, Columns, Lines, Where Relevant	1
Initials"	No.'	Office ³	Number ⁴	Kind (if l	Code ^o known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ° ·
									
		ļ <u> </u>							4
	_								
	-								
		 				· · · · · · · · · · · · · · · · · · ·			+
		 				- /····			
							 		
		<u> </u>					L	<u> </u>	ــــــــــــــــــــــــــــــــــــــ

<u> </u>			
Examiner Signature	•	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1⁵ if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this Box→

1449B/PTO Rev. 10/95			U.S. Department of Commerce Patent and Trademark Office		Complete if Known	
NOV. 10/33			Tatentana Tracentan Cines	Application Number	10/810,356	
LIS	T OF PRIOR	ART	CITED BY	Filing Date	March 26, 2004	
	APPLI			First Named Inventor	Furst, Joseph G.	
	(use as many she			Group Art Unit	3731	
	,			Examiner Name	Unknown	
Sheet	5	of	6	Attorney Docket Number	ICON 2 13110-1	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	T²
		Abstract of Pharmacological Properties of Trapidil: Comparison with Other Coronary Vasodilators, Ohnishi H, Kosuzume H, Yamaguchi K, Sato M, Umehara S, Funato H, Itoh C, Suzuki K, Kitamura Y, Suzuki Y, Itoh R., Nippon Yakurigaku Zasshi. 1980 Sep;76(6):495-503.	
		Abstract of Effects of Trapidil on Thromboxane A2-induced Aggregation of Platelets, Ischemic Changes in Heart and Biosynthesis of Thromboxane A2, Ohnishi H, Kosuzume H, Hayashi Y, Yamaguchi K, Suzuki Y, Itoh R., Prostaglandins Med. 1981 Mar;6(3):269-81.	
		Abstract of Antithrombotic Activity and the Mechanism of Action of Trapidil (Rocornal), Suzuki Y, Yamaguchi K, Shimada S, Kitamura Y, Ohnishi H., Prostaglandins Leukot Med. 1982 Dec;9(6):685-95.	
		Abstract of Suppression of Fibroblast Proliferation In Vitro and of Myointimal Hyperplasia In Vivo by the Triazolopyrimidine, Trapidil, Tiell ML, Sussman II, Gordon PB, Saunders RN, Artery. 1983;12(1):33-50.	
		Influence of Cardiovascular Drugs on Platelet Aggregation, Forster W, Block HU, Giessler C, Heinroth I, Mentz P, Ponicke K, Rettkowski W, Zehl U.,: Adv Myocardiol. 1983;4:539-47.	<u>.</u>
		Abstract of Trapidil in Preventing Restenosis After Balloon Angioplasty in the Ather Osclerotic Rabbit, MW Liu, GS Roubin, KA Robinson, AJ Black, JA Hearn, RJ Siegel, and SB King, 3d Circulation 1990 81: 1089-1093.	
		Abstract of Effects of Trapidil (Triazolopyrimidine), a Platelet-Derived Growth Factor Antagonist, in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty, Okamoto S, Inden M, Setsuda M, Konishi T, Nakano T, Am Heart J. 1992 Jun;123(6):1439-44.	
		Abstract of Trapidil (triazolopyrimidine), A Platelet-Derived Growth Factor Antagonist, Reduces Restenosis After Percutaneous Transluminal Coronary Angioplasty. Results of the Randomized, Double-Blind STARC Study. Studio Trapidil Versus Aspirin Nella Restenosi Coronarica, A Maresta, M Balducelli, L Cantini, A Casari, R Chioin, M Fabbri, A Fontanelli, PA Monici Preti, S Repetto, and S De Serv, Circulation, Dec 1994; 90: 2710 - 2715.	
=6		Abstract of The Trapidil Restenosis Trial (STARC study): Background, Methods and Clinical Characteristics of the Patient Population, Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fontanelli A, Monici Preti PA, Repetto S, Raffaghello S., Clin Trials Metaanal. 1994 Apr;29(1):31-40.	
		Abstract of Fast and Reproducible Vascular Neointima Formation in the Hamster Carotid Artery: Effects of Trapidil and Captopril, Matsuno H, Stassen JM, Hoylaerts MF, Vermylen J, Deckmyn H., Thromb Haemost. 1995 Dec;74(6):1591-6.	
		-New Aspects in Antithrombotic TherapyPlatelet Inhibitors-, Terres W, Meinertz T., Herz. 1996 Feb;21(1):1-11.	
		Management of restenosis after Coronary Intervention, Dangas G, Fuster V., Am Heart J. 1996 Aug;132(2 Pt 1):428-36.	

- .	l	
Examiner	Date	
Signature	Considered	
-		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Arlington, Virginia 22313-1450

Please type a plus sign (+) inside this Box→

1449B/PTO Rev. 10/95			U.S. Department of Commerce Patent and Trademark Office		Complete if Known	
1011 10100				Application Number	10/810,356	
LIS	T OF PRIOR	ART	CITED BY	Filing Date	March 26, 2004	
APPLICANT				First Named Inventor	Furst, Joseph G.	
	(use as many shee		-	Group Art Unit	3731	
	•			Examiner Name	Unknown	
Sheet	6	of	6	Attorney Docket Number	ICON 2 13110-1	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.					
		Results of a Meta-Analysis of Trapidil, a PDGF Inhibitor Ã' A Sufficient Reason for a Second Look to the Pharmacological Approach to Restenosis, Serruys PW, Banz K, Darcis T, Mignot A, van Es GA, Schwicker D., J Invasive Cardiol. 1997 Oct;9(8):505-512.					
		A Randomized Comparison of Trapidil (triazolopyrimidine), a Platelet-Derived Growth Factor Antagonist, Versus Aspirin in Prevention of Angiographic Restenosis after Coronary Artery Palmaz-Schatz Stent Implantation, Galassi AR, Tamburino C, Nicosia A, Russo G, Grassi R, Monaco A, Giuffrida G., Catheter Cardiovasc Interv. 1999 Feb;46(2):162-8					
		Reference Chart Derived From Post-Stent-Implantation Intravascular Ultrasound Predictorsof 6-Month Expected Restenosis on Quantitative Coronary Angiography, P. J. de Feyter, P. Kay, C. Disco, and P. W. Serruys, Circulation, Oct 1999; 100: 1777 - 1783.					
		Trapidil Inhibits Monocyte Chemoattractant Protein-1 and macrophage Accumulation After Balloon Arterial Injury in Rabbits, Poon M, Cohen J, Siddiqui Z, et al., Lab Invest. 1999;79:1369–1375.					
		The TRAPIST study - A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound, P.W. Serruys, D.P. Foley, M. Pieper, J.A. de Feyter on behalf of the TRAPIST investigators, European Heart Journal (2001) 22, 1938-1947, doi:10.1053/euhj.2001.2627, available online at http://www.idealibrary.com					
		•					

Examiner Signature	Date Considered	
-----------------------	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Arlington, Virginia 22313-1450